Related Experiment Video
Updated: May 12, 2026

Titration ELISA as a Method to Determine the Dissociation Constant of Receptor Ligand Interaction
Published on: February 15, 2018
Constitutively active ALK2 receptor mutants require type II receptor cooperation
Jana Bagarova1, Ashley J Vonner, Kelli A Armstrong
1Department of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Abstract:
Constitutively activating mutations in receptor kinases recruit downstream effector pathways independently of upstream signaling, with consequences ranging from developmental syndromes to cancer. Classic fibrodysplasia ossificans progressiva (FOP) is a congenital syndrome resulting from highly conserved activating mutations of the glycine-serine-rich (GS) regulatory domain of ACVR1, encoding bone morphogenetic protein (BMP) type I receptor ALK2, which lead to inappropriate signaling and heterotopic ossification of soft tissues. It is unclear if constitutively active mutant ALK2 receptors (caALK2) can function independently of signaling complexes with type II receptors and ligands. We found that ablation of BmpRII and ActRIIa abrogated BMP ligand-mediated and caALK2-mediated signaling and transcription in cells and disrupted caALK2-induced heterotopic ossification in mice. Signaling via GS domain ALK2 mutants could be restored by the expression of either BMP type II receptor. The contribution of BMP type II receptors was independent of their ligand-binding or kinase function but was dependent upon an intact cytoplasmic domain. These data demonstrate that GS domain ALK2 mutants act independently of upstream signaling but may require a nonenzymatic scaffolding function provided by type II receptors to form functional, apparently ligand-independent signaling complexes. These findings define the minimal requirements for signaling of GS domain ALK2 mutants, with implications for the therapeutic targeting of their activity in disease.
Insights
Constitutively active mutant ALK2 receptors driving fibrodysplasia ossificans progressiva (FOP) require type II receptors for signaling. This interaction is independent of ligand binding or kinase activity, highlighting a nonenzymatic scaffolding role for therapeutic insights.
Area of Science:
- Molecular Biology
- Cell Signaling
- Developmental Biology
Background:
- Activating mutations in receptor kinases, like ACVR1 in fibrodysplasia ossificans progressiva (FOP), lead to aberrant signaling and disease.
- The precise mechanism by which constitutively active ALK2 mutants (caALK2) signal, particularly their dependence on type II receptors and ligands, remains unclear.
Purpose of the Study:
- To investigate whether constitutively active ALK2 receptors can signal independently of type II receptors and ligands.
- To define the minimal requirements for caALK2 signaling and its role in heterotopic ossification.
Main Methods:
- Utilized cell-based assays and mouse models with genetic ablation of BMP type II receptors (BmpRII and ActRIIa).
- Assessed signaling, transcription, and heterotopic ossification phenotypes.
Main Results:
- Ablation of BmpRII and ActRIIa abrogated both BMP ligand-mediated and caALK2-mediated signaling and transcription.
- caALK2-induced heterotopic ossification in mice was disrupted upon type II receptor ablation.
- Signaling by GS domain ALK2 mutants could be restored by expressing either BMP type II receptor, independent of ligand binding or kinase activity, but dependent on the cytoplasmic domain.
Conclusions:
- Constitutively active ALK2 mutants signal independently of upstream pathways but require a nonenzymatic scaffolding function from type II receptors.
- Type II receptors are essential for forming functional, potentially ligand-independent signaling complexes with caALK2.
- These findings provide critical insights into the minimal requirements for caALK2 signaling, informing therapeutic strategies for FOP and related conditions.
More Related Videos
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
15:28Mutagenesis and Functional Analysis of Ion Channels Heterologously Expressed in Mammalian Cells
Published on: October 1, 2010
Related Concept Videos
The Two-State Receptor Model
The binding affinity of a drug determines its interaction with one...
Cooperative Allosteric Transitions
Cooperative Allosteric Transitions
Cooperative Allosteric Transitions
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Drug-Receptor Interactions
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.